Compositions and methods for treating conditions related to increased eosinophils
Disclosed herein are methods of treating diseases associated with increased numbers of eosinophils basophils, and/or neutrophils with R(+) pramipexole.
1. A method of treating eosinophilic esophagitis in a human subject comprising: administering to the human subject in need thereof a therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the human subject has above about 450 eosinophil cells per microliter in the peripheral blood.
3. The method of claim 1 , wherein the therapeutically effective amount is from about 50 mg to about 1,500 mg per day.
4. The method of claim 1 , wherein the therapeutically effective amount is from about 150 mg to about 1,500 mg per day.
5. The method of claim 1 , wherein the therapeutically effective amount is from about 150 mg to about 300 mg per day.
6. The method of claim 1 , wherein administering comprises administering a fraction of the daily dose two or more times per day.
7. The method of claim 1 , wherein administering comprises administering a dose equal to about half of a daily dose twice per day.
8. The method of claim 7 , wherein the dose is administered every 12 hours.
9. The method of claim 1 , wherein administering comprises administering about 150 mg two times per day.
10. The method of claim 1 further comprising monitoring the subject.
11. The method of claim 1 further comprising monitoring the subject for neutropenia.
12. The method of claim 1 , further comprising an induction step comprising administering a second therapeutic agent that is capable of decreasing eosinophil levels.
13. The method of claim 12 , wherein the second therapeutic agent is selected from a glucocorticoid, a non-steroidal anti-inflammatory drug (NSAIDs), phenolic antioxidants, anti-proliferative drug, or a combination thereof.
14. The method of claim 12 , wherein said induction step is from about 1 week to about 6 months.
15. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 1,200 mg.
16. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 1,500 mg.
17. The method of claim 1 , wherein the therapeutically effective amount is about 75 mg two times per day.
18. The method of claim 1 , wherein the therapeutically effective amount is about 37.5 mg two times per day.
19. The method of claim 1 , wherein the therapeutically effective amount is about 225 mg two times per day.
20. The method of claim 1 , wherein the therapeutically effective amount is about 300 mg two times per day.
21. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 75 mg per day.
22. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 150 mg per day.
23. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 300 mg per day.
24. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 450 mg per day.
25. The method of claim 1 , wherein said therapeutically effective amount of R(+) pramipexole is about 600 mg per day.
26. The method of claim 1 , wherein the therapeutically effective amount of R(+) pramipexole, or a pharmaceutically acceptable salt thereof, is administered as an initial dosing regimen followed by administration of a therapeutically effective amount of R(+) pramipexole or a pharmaceutically acceptable salt thereof as a maintenance dosing regimen, wherein the therapeutically effective amount of R(+) pramipexole, or a pharmaceutically acceptable salt thereof, administered during the initial dosing regimen is from about 300 milligrams to about 600 milligrams per day, and wherein the therapeutically effective amount of R(+) pramipexole, or a pharmaceutically acceptable salt thereof, administered during the maintenance dosing regimen is from about 75 milligrams to about 150 milligrams per day.